(Q40794894)

23 September 2017

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis (English)

1 reference

23 September 2017

1 reference

1 reference

Mould DR

1

1 reference

23 September 2017

Davis CB

2

1 reference

23 September 2017

Minthorn EA

3

1 reference

23 September 2017

Kwok DC

4

1 reference

23 September 2017

Elliott MJ

5

1 reference

23 September 2017

Luggen ME

6

1 reference

23 September 2017

Totoritis MC

7

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

Clinical Pharmacology & Therapeutics

23 September 2017

1 reference

23 September 2017

66

1 reference

23 September 2017

3

1 reference

23 September 2017

246-257

1 reference

The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Comparison of four basic models of indirect pharmacodynamic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Characterization of four basic models of indirect pharmacodynamic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Human CD4 modulation in vivo induced by antibody treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

Treatment with anti-CD4 monoclonal antibody and acute interstitial nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2899%2970032-9

10.1016/S0009-9236(99)70032-9

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference